Zevalin
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Non-Hodgkin’s lymphoma (NHL) comprises a clinically and biologically heterogeneous group of lymphoproliferative disorders…
Purpose: Both anti-CD20 antibodies (ibritumomab; ZEVALIN® and tositumomab; BEXXAR®) currently used for radioimmunotherapy of B…
Abdominal wall sarcomas are rare tumors with a high recurrence rate. We present the case report of a 48-yearold female patient…
There are conflicting statements in the literature on the optimum shielding for beta emitting radionuclides. Perspex is commonly…
Unlike conventional radiation, Yttrium-90-ibritumomab tiuxetan (Zevalin) induces cellular damage only in the targeted tumor cells…
High-dose chemotherapy and autologous stem-cell transplantation (autoSCT) have an established therapeutic role in patients (pts…
Ibritumomab is the murine parent anti-CD20 antibody that was engineered to make the human chimeric antibody rituximab. Tiuxetan…
Ibritumomab tiuxetan (Zevalin) is the first radioimmunoconjugate to receive FDA approval for the treatment of cancer. The drug is…
Approximately 55,400 new cases of non-Hodgkin's lymphoma (NHL) are diagnosed each year, with the overall prevalence of the…